Mirae Asset Global Investments
TARS icon

Mirae Asset Global Investments’s Tarsus Pharmaceuticals TARS Stock Holding History

Mirae Asset Global Investments’s Portfolio TARS Stock Details TARS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$121K Sell
1,924
-296
-13% -$18.9K ﹤0.01% 1202
2026
Q1 		$156K Buy
2,220
+157
+8% +$11K ﹤0.01% 1106
2025
Q4 		$169K Buy
2,063
+431
+26% +$32.2K ﹤0.01% 1169
2025
Q3 		$97K Buy
1,632
+9
+0.6% +$443 ﹤0.01% 1218
2025
Q2 		$65.7K Buy
1,623
+339
+26% +$15.3K ﹤0.01% 1220
2025
Q1 		$66.4K Buy
1,284
+10
+0.8% +$494 ﹤0.01% 1188
2024
Q4 		$70.1K Sell
1,274
-102
-7% -$4.63K ﹤0.01% 1208
2024
Q3 		$44.7K Buy
1,376
+248
+22% +$6.97K ﹤0.01% 1320
2024
Q2 		$28.4K Buy
+1,128
New +$37.9K ﹤0.01% 1339
2024
Q1 		– Sell
-11,226
Closed -$227K – 2642
2023
Q4 		$227K Buy
11,226
+63
+0.6% +$1.05K ﹤0.01% 2298
2023
Q3 		$198K Buy
+11,163
New +$198K ﹤0.01% 2300

Other funds holding TARS

Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return
EOJOAM
E. Ohman J:or Asset Management Stockholm, Sweden $4.3B AUM 29.55% 1-Year Est. Return
AA
ALPS Advisors Denver, Colorado $21.3B AUM 23.41% 1-Year Est. Return
Vontobel Holding
Vontobel Holding Zurich, Switzerland $31.4B AUM 31.97% 1-Year Est. Return

Mirae Asset Global Investments's TARS Position: Q2 2026 in Review

Mirae Asset Global Investments reduced its Tarsus Pharmaceuticals (TARS) stake by 13% in Q2 2026, selling an estimated $18.9K and leaving 1,924 shares worth $121K. The position accounts for ﹤0.01% of the portfolio, ranked #1202.

Mirae Asset Global Investments first reported a position in TARS in Q3 2023 and has held it in 11 quarters since. The position peaked at $227K in Q4 2023. 53 funds tracked by Wall St. Rank hold TARS as of Q2 2026.

  • Mirae Asset Global Investments held 1,924 shares of Tarsus Pharmaceuticals worth $121K as of Q2 2026.
  • Mirae Asset Global Investments sold 296 Tarsus Pharmaceuticals shares in Q2 2026, an estimated $18.9K.
  • Tarsus Pharmaceuticals made up ﹤0.01% of Mirae Asset Global Investments's portfolio in Q2 2026, its #1202 holding.
  • Mirae Asset Global Investments first reported a position in Tarsus Pharmaceuticals in Q3 2023 and has held it in 11 quarters since.
  • Mirae Asset Global Investments's Tarsus Pharmaceuticals position peaked at $227K in Q4 2023.
  • 53 funds tracked by Wall St. Rank held Tarsus Pharmaceuticals as of Q2 2026.

Based on Mirae Asset Global Investments's 13F filing for Q2 2026, filed 22 Jul 2026.